肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2012年
9期
600-602
,共3页
赵树强%贾春生%王桂琴%李淑勤
趙樹彊%賈春生%王桂琴%李淑勤
조수강%가춘생%왕계금%리숙근
癌,非小细胞肺%流式细胞术%Th17细胞%白细胞介素-17
癌,非小細胞肺%流式細胞術%Th17細胞%白細胞介素-17
암,비소세포폐%류식세포술%Th17세포%백세포개소-17
Carcinoma,non-small cell lung%Flow cytometry%Th17 cells%Interleukin-17
目的 探讨非小细胞肺癌(NSCLC)患者外周血Th17细胞比例和自细胞介素-17(IL-17)水平的变化及其与患者临床病理的关系.方法 收集60例原发未治疗的NSCLC患者(NSCLC组)和20例健康志愿者(对照组),采用流式细胞术(FCM)检测Th17细胞比例,采用酶联免疫吸附试验(ELISA)检测血清IL-17水平.结果 NSCLC组Th17细胞占CD+3 T细胞比例高于对照组[(1.23±0.41)％比(1.05±0.28)％,t=1.679,P=0.097],鳞状细胞癌患者外周血Th17细胞比例明显高于腺癌患者[(1.31±0.39)％比(1.09±0.41)％,t=2.093,P=0.041].NSCLC组IL-17水平明显高于健康对照组[(21.11±7.87) pg/ml比(17.64±5.07)pg/ml,t=2.280,P=0.027],鳞状细胞癌患者血清IL-17表达水平明显高于腺癌患者[(23.11±8.73) pg/ml比(18.54±6.38)pg/ml,t=2.203,P=0.032].Th17细胞比例、IL-17的表达水平随临床分期的进展呈下降趋势[F=3.151,P=0.032;F=4.132,P=0.010].结论 NSCLC患者外周血中Th17细胞比例和IL-17的表达与肿瘤病理分型、TNM分期相关,可能在NSCLC的病程中发挥重要作用.
目的 探討非小細胞肺癌(NSCLC)患者外週血Th17細胞比例和自細胞介素-17(IL-17)水平的變化及其與患者臨床病理的關繫.方法 收集60例原髮未治療的NSCLC患者(NSCLC組)和20例健康誌願者(對照組),採用流式細胞術(FCM)檢測Th17細胞比例,採用酶聯免疫吸附試驗(ELISA)檢測血清IL-17水平.結果 NSCLC組Th17細胞佔CD+3 T細胞比例高于對照組[(1.23±0.41)％比(1.05±0.28)％,t=1.679,P=0.097],鱗狀細胞癌患者外週血Th17細胞比例明顯高于腺癌患者[(1.31±0.39)％比(1.09±0.41)％,t=2.093,P=0.041].NSCLC組IL-17水平明顯高于健康對照組[(21.11±7.87) pg/ml比(17.64±5.07)pg/ml,t=2.280,P=0.027],鱗狀細胞癌患者血清IL-17錶達水平明顯高于腺癌患者[(23.11±8.73) pg/ml比(18.54±6.38)pg/ml,t=2.203,P=0.032].Th17細胞比例、IL-17的錶達水平隨臨床分期的進展呈下降趨勢[F=3.151,P=0.032;F=4.132,P=0.010].結論 NSCLC患者外週血中Th17細胞比例和IL-17的錶達與腫瘤病理分型、TNM分期相關,可能在NSCLC的病程中髮揮重要作用.
목적 탐토비소세포폐암(NSCLC)환자외주혈Th17세포비례화자세포개소-17(IL-17)수평적변화급기여환자림상병리적관계.방법 수집60례원발미치료적NSCLC환자(NSCLC조)화20례건강지원자(대조조),채용류식세포술(FCM)검측Th17세포비례,채용매련면역흡부시험(ELISA)검측혈청IL-17수평.결과 NSCLC조Th17세포점CD+3 T세포비례고우대조조[(1.23±0.41)％비(1.05±0.28)％,t=1.679,P=0.097],린상세포암환자외주혈Th17세포비례명현고우선암환자[(1.31±0.39)％비(1.09±0.41)％,t=2.093,P=0.041].NSCLC조IL-17수평명현고우건강대조조[(21.11±7.87) pg/ml비(17.64±5.07)pg/ml,t=2.280,P=0.027],린상세포암환자혈청IL-17표체수평명현고우선암환자[(23.11±8.73) pg/ml비(18.54±6.38)pg/ml,t=2.203,P=0.032].Th17세포비례、IL-17적표체수평수림상분기적진전정하강추세[F=3.151,P=0.032;F=4.132,P=0.010].결론 NSCLC환자외주혈중Th17세포비례화IL-17적표체여종류병리분형、TNM분기상관,가능재NSCLC적병정중발휘중요작용.
Objective To investigate the relationship between the proportion of Th17 cells and IL-17 expression in the peripheral blood and their clinical significance in patients with non-small cell lung cancer (NSCLC).Methods The proportion of Th17 cells determined by flow cytometry (FCM) and IL-17 detected by enzyme-linked immunosorbent assay (ELISA).The data was analyzed from 60 untreated patients with NSCLC (NSCLC group) and 20 healthy volunteers (control group).Results The Th17 cells proportion in CD+3 T-cells in NSCLC group was significantly higher than that in control group [(1.23±0.41) ％ vs (1.05±0.28) ％,t =1.679,P =0.097].The expression levels of Th17 cells in peripheral blood of patients with squamous cell carcinoma was significantly higher than that in adenocarcinoma patients [(1.31±0.39) ％ vs (1.09±0.41) ％,t =2.093,P =0.041].The concentration of IL-17 of patients with NSCLC was significantly higher than that in control group [(21.11±7.87) pg/ml vs (17.64±5.07) pg/ml,t =2.280,P =0.027].The expression levels of serum IL-17 of squamous cell carcinoma patients was significantly higher than that of adenocarcinoma patients [(23.11±8.73) pg/ml vs (18.54±6.38) pg/ml,t =2.203,P =0.032].As clinical stage progressed,the proportion of Th17 cells and IL-17 expression were significantly downtrend [F =3.151,P =0.032,F =4.132,P =0.010].Conclusion The levels of Th17 cells and IL-17 in the peripheral blood of patients with NSCLC significantly correlated with the pathological types and TNM stage,might play an important role in the course of the disease.
